M Booth Health named Stacey Bernstein its new CEO on the heels of the global health communications consultancy’s strongest performing year marked by double-digit growth and multi-million dollar account wins. Bernstein replaces Tim Bird as he transitions into a consultative role.
Relevate Health is the new brand identity born out of the strategic combination between Relevate Health Group, a data-driven marketing products and services communications firm, and Arteric, a digital marketing consultancy whose engagements embody proprietary AI and machine learning (ML) driven analytics.
Peregrine Market Access, a leading consultant agency for the life sciences industry, earned its place as number 589 on the Inc. 5000 list of the nation’s fastest-growing private companies. The list represents a unique look at the most successful companies within a dynamic segment of the American economy—its independent small businesses.
International healthcare and communications group Huntsworth announced the acquisition of U.S.-based medical analytics consultancy MedEvoke.
Ashfield Advisory, an ecosystem of healthcare advisory and consulting businesses and part of UDG Healthcare plc., announced two senior leadership appointments.
Four more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.
Full-service health and wellness marketing agency Fingerpaint announced the appointment of Dr. Daniel Schroen as head of Photo 51, a consultancy launched during June 2020 that is focused solely on advanced therapeutics.
Full-service health and wellness agency Fingerpaint is forming Photo 51, a new consultancy focused solely on gene and cell therapies.
Stacey Singer, an agency growth specialist of 30 years, announced her recent departure from global powerhouse WPP to launch a consultancy focused on helping marketing communication agencies retain and grow business.
The cost of developing a new drug has nearly doubled since 2010 and the world’s 12 largest drugmakers are making the lowest return on their R&D investments in nine years, according to Deloitte.